Cardiovascular

Latest News

Cardiologist listening to patient's heart | Image credit: Space_Cat – stock.adobe.com

40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

By Hayden E. Klein

June 19th 2025

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

By Lisa M. Kern, MD, MPH
Joselyne E. Aucapina

June 3rd 2025

CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

By Hayden E. Klein

May 23rd 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

By Ofer Kobo, MD
Martin K. Rutter, MD

May 16th 2025

Doctor taking child's blood pressure | Image credit: romaset – stock.adobe.com

3 Maternal Risk Factors Linked to Elevated Offspring Blood Pressure

By Hayden E. Klein

May 14th 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

Watch Now

Continuing Medical Education

View All

June 19th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

June 19th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

June 19th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

September 16th 2020

CV Risk Reduction and Coverage of Therapies

September 16th 2020

Cardiovascular Disease Treatment Decisions and Cost

September 16th 2020

Cost-Effectiveness and Cardiovascular Risk

September 16th 2020

Implications for Treating Patients With Icosapent Ethyl

September 16th 2020

Coronary Plaque Regression and CV Risk

September 16th 2020

Interim Analysis of EVAPORATE

September 16th 2020

The REDUCE-IT Study and CV Risk

September 16th 2020

Targeting Triglycerides to Reduce CV Risk

September 16th 2020

Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors

September 16th 2020

PCSK9 Inhibitors and CV Risk

September 16th 2020

Statin Therapy: Risk for Future CV Events

September 16th 2020

Statin Therapy for LDL Reduction and CV Risk

September 16th 2020

Dyslipidemia: Strategies Used to Reduce CV Risk

September 16th 2020

Cardiovascular Risk Management

September 16th 2020

LDL Cholesterol Lowering and CV Risk

September 16th 2020

Risk Assessment for Cardiovascular Disease

September 16th 2020

Economic Burden of Cardiovascular Disease

July 25th 2020

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show

Mary Caffrey

Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning

July 17th 2020

Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone

Mary Caffrey

Transient ischemic attack is a common form of stroke, and 1 in 4 stroke survivors go on to experience a second stroke—most within the first month.

June 16th 2020

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure

Mary Caffrey

A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.

June 16th 2020

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.

June 14th 2020

Is Prevention the Future of SGLT2s? Inzucchi Offers Data That Suggest "Yes"

Mary Caffrey

Yale's Silvio Inzucchi, MD, who has been involved in groundbreaking trials with SGLT2 inhibitors for the past decade, shared data that show patients who did not have type 2 diabetes (T2D) when they started the DAPA-HF trial were 32% less likely to develop the disease if they took dapagliflozin (Farxiga) instead of placebo.

June 13th 2020

Cardiovascular Benefits of Vascepa Greater for Those With Diabetes, New REDUCE-IT Data Show

Mary Caffrey

When it comes to diabetes, lead study author Deepak L. Bhatt, MD, MPH, said clinicians and payers should weigh the considerable costs of what happens when a patient suffers a heart attack or stroke when deciding on a treatment regimen.

June 12th 2020

Dr Darren K. McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention

In a debate at the American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will discuss whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready to be used for primary cardiovascular prevention.

April 16th 2020

American Heart Association Offers Guidance on Diabetes, Coronary Artery Disease

Gianna Melillo

Recently, it has been shown that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. For this reason, along with increasing prevalence of type 2 diabetes (T2D), effective, patient-centered management of coronary artery disease (CAD) in patients with diabetes is imperative to optimize patient outcomes, the American Heart Association said.

April 6th 2020

What We're Reading: Coronavirus-Related Heart Issues; Racial Disparities in COVID-19 Outcomes; Urging Smokers to Quit

AJMC Staff

Coronavirus disease 2019 (COVID-19) was linked with cardiovascaluar issues and cardiac arrest; African Americans were shown to have higher rates of infection and death due to COVID-19; health experts call for smokers to cease use and manufacturers to halt production.

March 30th 2020

A Q&A on Smoking Cessation With E-Cigarettes, REDUCE-IT Trial Findings

Matthew Gavidia

The American Journal of Managed Care® (AJMC® ) interviewed Martha Gulati, MD, cardiologist at Banner – University Medicine Heart Institute, on findings of eicosapentaenoic acid (EPA) levels in relation to cardiovascular outcomes and smoking cessation with e-cigarettes. These studies are part of the 2020 American College of Cardiology / World Congress of Cardiology Virtual Experience.

March 29th 2020

Dr Javed Butler Notes Subgroup Efficacy Differences of Vericiguat in VICTORIA Trial Findings

In VICTORIA, patients within the first 3 quartiles of peptide elevation had results more impressive than the overall findings. However, patients with the highest quartile did not seem to benefit. This raises the question whether the sickest of the sick patients will benefit from vericiguat, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.

March 28th 2020

Dr Richard Kovacs on How ACC Is Leading the Charge for Credible Clinical Data Amid COVID-19

We need more than ever credible clinical data both on the pandemic, but also how to understand how the pandemic’s going to affect patients in the cardiovascular field, said Richard Kovacs, MD, FACC, clinical cardiologist and president of the American College of Cardiology (ACC).

March 28th 2020

Dr Javed Butler on Key Takeaways of Vericiguat Found in VICTORIA Trial Participants With HFrEF

Results from VICTORIA show vericiguat produced a 10% relative risk reduction in the highest-risk patients with heart failure. Study patients had about 3 times the health risk seen in recent heart failure trials, which showed higher relative risk reductions. However, VICTORIA saw a 4% absolute risk reduction, which is the same as the others, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.

...

4 5 6 7 8 9 10 11 12

...

24 >